11 A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.

12 Clinical and cost outcomes of pre-emptive plerixafor administration in patients with multiple myeloma undergoing stem cell mobilization.

13 Bacteremias following autologous stem cell transplantation for multiple myeloma: Risk factors and outcomes.

14 Outcomes of autologous transplantation for multiple myeloma according to different induction regimens

15 Targeting of stromal versican by miR-144/199 inhibits multiple myeloma by downregulating FAK/STAT3 signaling.

16 Is regular laryngoscopy necessary for multiple myeloma patients? Case report and review of literature

17 Acute gouty arthritis and rapidly progressive renal failure as manifestation of multiple myeloma: clinical case description

18 The Transcription factor PU.1 mediates enhancer-promoter looping that is required for IL-1b eRNA and mRNA transcription in mouse myeloma and macrophage cell lines.

19 Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.

20 2,4-Dihydroxy-3'-methoxy-4'-ethoxychalcone suppresses cell proliferation and induces apoptosis of multiple myeloma via the PI3K/akt/mTOR signaling pathway

21 Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: the TOURMALINE-MM3 trial.

22 Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

23 Synchronous renal cell carcinoma and multiple myeloma: report of two cases and review of the literature.

24 Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology

25 Response to Comment—Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology

26 Patients' experiences of living with multiple myeloma.

27 CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents.

28 CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy

29 Mass Cytometry Discovers Two Discrete Subsets of CD39−Treg Which Discriminate MGUS From Multiple Myeloma

30 Genetic Basis of Extramedullary Plasmablastic Transformation of Multiple Myeloma.

31 High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma.

32 International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma.

33 Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial

34 Progressive multifocal leucoencephalopathy associated with multiple myeloma

35 (Bortezomib plus lenalidomide/thalidomide)- vs (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials

36 Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

37 Real world Italian experience of pomalidomide plus low-dose dexamethasone in the relapsed and refractory myeloma setting: extended follow-up of a retrospective multicenter study by the 'Rete Ematologica Pugliese E Basilicata'

38 Hyperphosphatemia in multiple myeloma

39 Using a digital patient powered research network to identify outcomes of importance to patients with multiple myeloma.

40 Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-centre analysis over a 12-year period

41 Visceral leishmaniasis infection in a refractory multiple myeloma patient treated with bortezomib

42 Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan

43 light chain myeloma induced severe hypertriglyceridemia

44 concurrent presentation of hodgkin lymphoma and multiple myeloma

45 crescentic glomerulonephritis in iga multiple myeloma: a case report

46 ultrasound-guided emergency pericardiocentesis of a patient with multiple myeloma in a resource limited setting

47 evodiamine selectively inhibits multiple myeloma cell growth by triggering activation of intrinsic apoptosis pathway

48 plasmablastic myeloma presenting as rapidly progressive renal failure in a young adult

49 multiple myeloma cells express key immunoregulatory cytokines and modulate the monocyte migratory response

50 infections in hospitalised patients with multiple myeloma: main characteristics and risk factors

51 celastrol attenuates the invasion and migration and augments the anticancer effects of bortezomib in a xenograft mouse model of multiple myeloma

52 polydatin regulates proliferation, apoptosis and autophagy in multiple myeloma cells through mtor/p70s6k pathway

53 prevalence of medication-related osteonecrosis of the jaw in patients with breast cancer, prostate cancer, and multiple myeloma

54 circulating cd3+cd4+cd161+ cells are associated with early complications after autologous stem cell transplantation in multiple myeloma

55 immunological dysregulation in multiple myeloma microenvironment

56 targeting ongoing dna damage in multiple myeloma: effects of dna damage response inhibitors on plasma cell survival

57 long-term outcome after autologous stem cell transplantation with adequate peripheral blood stem cell mobilization using plerixafor and g-csf in poor mobilizer lymphoma and myeloma patients

58 mieloma múltiplo neste fascículo multiple myeloma in this issue

59 ascites in the course of plasma cell myeloma complicated by al amyloidosis

60 oral lesion as unusual first manifestation of multiple myeloma: case reports and review of the literature

61 anti-multiple myeloma drug-associated taste dysfunction: an analysis of the faers database

62 effectiveness of treatment of an elderly patient with good prognosis of multiple myeloma

63 concomitant occurrence of multiple myeloma with diffuse large b-cell lymphoma

64 changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: a prospective multicenter study

65 inhibition of p-selectin and psgl-1 using humanized monoclonal antibodies increases the sensitivity of multiple myeloma cells to bortezomib

66 early application of high cut-off haemodyalisis for de-novo myeloma nephropathy is associated with long-term dialysis-independency and renal recovery

67 massive retroperitoneal hemorrhage as an initial presentation of a rare and aggressive form of multiple myeloma

68 primary biliary cirrhosis and igg-kappa type multiple myeloma both respond well to vincristine, adriamycin and dexamethasone: is there a pathogenic relationship?

69 carfilzomib boosted combination therapy for relapsed multiple myeloma

70 lung postmortem autopsy revealing extramedullary involvement in multiple myeloma causing acute respiratory distress syndrome

71 pulmonary-renal syndrome as a clinical expression of multiple myeloma

72 brain abscesses caused by nocardia paucivorans in a multiple myeloma patient treated with lenalidomide and dexamethasone: a case report and review of literature.

73 a 54-year-old woman with donor cell origin of multiple myeloma after allogeneic hematopoietic stem cell transplantation for the treatment of cml

74 a case of internal carotid artery thrombosis associated with thalidomide administration in multiple myeloma

75 inflammatory and anti-inflammatory equilibrium, proliferative and antiproliferative balance: the role of cytokines in multiple myeloma

76 hematopoietic stem cell mobilization for autologous transplantation in multiple myeloma patients previously exposed to cyclophosphamide, thalidomide, and dexamethasone: is granulocyte-colony stimulating factor alone enough?

77 tratamento do mieloma múltiplo recidivado relapsed multiple myeloma treatment

78 serum parathyroid hormone is a new potential risk factor in multiple myeloma

79 development and validation of an algorithm to identify patients with multiple myeloma using administrative claims data

80 high serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment

81 mieloma múltiplo: 50 casos diagnosticados por citometria de fluxo multiple myeloma: 50 cases diagnosed by flow cytometry

82 treatment of multiple myeloma at clinical department of hematology, university medical centre ljubljana with autologous hematopoietic stem cell transplantation in years 2014 and 2015

83 cd38 ligation in peripheral blood mononuclear cells of myeloma patients induces release of protumorigenic il-6 and impaired secretion of ifnγ cytokines and proliferation

84 cytodiagnosis of multiple myeloma presenting as chest wall swellings

85 treatment of multiple myeloma patients with autologous stem cell transplantation — a fresh analysis

86 management of multiple myeloma and usage of bortezomib: perspective from india and ukraine

87 single-dose anti-cd138 radioimmunotherapy: bismuth-213 is more efficient than lutetium-177 for treatment of multiple myeloma in a preclinical model

88 proliferative glomerulonephritis with masked monoclonal deposits responsive to myeloma therapy

89 metastatic pulmonary calcinosis and leukocytoclastic vasculitis in a patient with multiple myeloma

90 smoldering multiple myeloma

91 systemic mastocytosis with smoldering multiple myeloma: report of a case

92 transferrin-conjugated snalps encapsulating 2′-o-methylated mir-34a for the treatment of multiple myeloma

93 incb16562, a jak1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support

94 detection of paroxysmal nocturnal hemoglobinuria-phenotype in patients with chronic lymphocytic leukemia and multiple myeloma

95 immunophenotype of normal and myelomatous plasma cell subsets

96 Real-world treatment outcomes in multiple myeloma: Multicenter registry results from Finland 2009-2013.

97 Real-world effectiveness and safety of daratumumab, bortezomib and dexamethasone in relapsed/refractory multiple myeloma in Slovakia.

98 Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry

99 Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score

100 Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

101 Continuous lenalidomide treatment for newly diagnosed multiple myeloma

Keyword Connections

Journals

Research Groups

Bibliographies